02.26.15
Morrisville, N.C.-based TearScience Inc., which makes treatments for meibomian gland dysfunction (MGD), has appointed a new president and CEO. Joseph Boorady, O.D., joins TearScience from Carl Zeiss Meditec Inc. where he was senior vice president of U.S. sales, marketing, and customer service for all medical products.
Boorady replaces current CEO and co-founder Tim Willis.
“Boorady’s professional expertise and commercial track record make him the ideal candidate to lead TearScience to the next level,” said Willis. “TearScience technology has already improved care for tens of thousands suffering from MGD [which causes dry eye], with significant opportunity for ongoing education and treatment to help millions with the disease. Joe’s proven industry expertise will provide the energy to vastly expand use of the breakthrough LipiView II and LipiFlow devices.”
Boorady’s over 20 years in the industry as an eye care professional, educational leader, entrepreneur and corporate executive began after graduating in 1993 from the State University of New York (SUNY) College of Optometry with clinical honors. He has 13 years of clinical experience as the founder and owner of several primary eye care practices in New York and New Jersey, and 10 years with SUNY College of Optometry, where his last position was vice president clinical affairs and executive director overseeing 36 clinics throughout New York City. Boorady then spent three years as an equity partner and chief operating officer of an eye care software start-up. He also studied at Harvard Business School. Most recently, he joined Carl Zeiss Meditec in 2009 where he led significant U.S. growth at the ophthalmic technology giant.
“It is an honor to join TearScience, a company that has pioneered the most advanced technologies in dry eye and MGD,” said Boorady. “We thank Tim for all of his valuable contributions to the company, I hope to use my years of industry experience to complement the already impressive team that has brought innovation to the market and a commitment to helping eye care professionals diagnose and more effectively treat MGD.”
The TearScience System, which includes Lipiview II, the Korb Meibomian Gland Evaluator, and Lipiflow, is designed identify, diagnose, and treat MGD, a chronic and progressive disease that disrupts the tear film and vision clarity, causes ocular discomfort and is the root cause of most dry eye.
Boorady replaces current CEO and co-founder Tim Willis.
“Boorady’s professional expertise and commercial track record make him the ideal candidate to lead TearScience to the next level,” said Willis. “TearScience technology has already improved care for tens of thousands suffering from MGD [which causes dry eye], with significant opportunity for ongoing education and treatment to help millions with the disease. Joe’s proven industry expertise will provide the energy to vastly expand use of the breakthrough LipiView II and LipiFlow devices.”
Boorady’s over 20 years in the industry as an eye care professional, educational leader, entrepreneur and corporate executive began after graduating in 1993 from the State University of New York (SUNY) College of Optometry with clinical honors. He has 13 years of clinical experience as the founder and owner of several primary eye care practices in New York and New Jersey, and 10 years with SUNY College of Optometry, where his last position was vice president clinical affairs and executive director overseeing 36 clinics throughout New York City. Boorady then spent three years as an equity partner and chief operating officer of an eye care software start-up. He also studied at Harvard Business School. Most recently, he joined Carl Zeiss Meditec in 2009 where he led significant U.S. growth at the ophthalmic technology giant.
“It is an honor to join TearScience, a company that has pioneered the most advanced technologies in dry eye and MGD,” said Boorady. “We thank Tim for all of his valuable contributions to the company, I hope to use my years of industry experience to complement the already impressive team that has brought innovation to the market and a commitment to helping eye care professionals diagnose and more effectively treat MGD.”
The TearScience System, which includes Lipiview II, the Korb Meibomian Gland Evaluator, and Lipiflow, is designed identify, diagnose, and treat MGD, a chronic and progressive disease that disrupts the tear film and vision clarity, causes ocular discomfort and is the root cause of most dry eye.
